SCHEMBL5688596

SCHEMBL5688596

Cc1ccnc(CCc2ccc(OC(=O)N3CCC(Oc4ccc(C(=O)O)cc4)CC3)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.44
SRD5A1 P18405 1/20 0.42
LMNA P02545 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EPHX2 P34913 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2J2 P51589 1/20 0.41
ALDH1A1 P00352 2/20 0.40
SSTR5 P35346 1/20 0.40
KCNH2 Q12809 2/20 0.39
HRH1 P35367 1/20 0.39
CCR3 P51677 1/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690002 0.92 SRD5A2 (0.45) SRD5A2SRD5A1LMNANPC1RAB9A
SCHEMBL5688310 0.91 EPHX2 (0.44) LMNANPC1RAB9AMEN1KMT2A
SCHEMBL5690284 0.88 GRIN2B (0.43) SSTR5KCNH2NOS3NOS1NOS2
SCHEMBL5687972 0.86 SRD5A2 (0.45) SRD5A2SRD5A1LMNANPC1RAB9A
SCHEMBL5687756 0.85 LIPE (0.41) NPC1RAB9AALDH1A1KCNH2SCN5A
SCHEMBL5688450 0.85 LIPE (0.45) LNPEP
SCHEMBL5687849 0.83 KMT2A (0.54) SRD5A2SRD5A1LMNANPC1RAB9A
SCHEMBL5687649 0.83 EPHX2 (0.44) MEN1KMT2AL3MBTL1EPHX2ALDH1A1
SCHEMBL5690173 0.82 SRD5A1 (0.45) SRD5A2SRD5A1LMNANPC1RAB9A
SCHEMBL5715212 0.81 HRH3 (0.43) LMNARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC SRD5A2 2052/4885SRD5A1 1719/4885LMNA 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.